Navigation Links
New data showed Actos prevented progression of atherosclerotic plaque volume in patients
Date:3/31/2008

reatment.

The data showed that patients treated with glimepiride, a sulfonylurea and commonly used diabetes medication, exhibited progression of coronary atherosclerosis. In contrast, the ACTOS arm showed no progression of coronary atherosclerosis over the 18-month period from the initial baseline measurement.

Cardiovascular safety data was collected by looking at macrovascular events and episodes of congestive heart failure (CHF). The number of episodes of a common cardiovascular endpoint of cardiovascular mortality, non-fatal MI, or non-fatal stroke was 6 (2.2%) in glimepiride patients and 5 (1.9%) in ACTOS-treated patients. The number of hospitalizations due to CHF was equivalent in both arms. In the ACTOS-treated group, eight patients experienced a bone fracture, none involving the hip or spine.

Atherosclerosis is a condition that leads to reduced or blocked blood flow, and is accelerated in patients with type 2 diabetes. Atherosclerosis-related cardiovascular disease is the leading cause of death and disability in people with type 2 diabetes. Published data shows that slowed progression and reductions in atheroma volume lessens the incidence of a second heart attack. IVUS measures the volume of plaque build-up in the coronary arteries, a marker of coronary atherosclerosis.

The data are consistent with the findings of the CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne) trial. Both PERISCOPE and CHICAGO support the findings of the PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events) trial, which showed that ACTOS was not associated with an increased risk of heart attack, stroke or death.


'/>"/>

Contact: Amy Losak
amy.losak@ketchum.com
917-865-6688
Takeda Pharmaceuticals North America
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
2. Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
3. Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
4. New study of Concerta showed significant improvement of ADHD symptom management in adults
5. African Americans at Risk for Low Calcium Intake - New Survey Finds Those Experiencing Symptoms of Lactose Intolerance May be Sidelining Dairy in Their Diets
6. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
7. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
8. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
9. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
10. One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
11. One third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Current students of Ramtha’s School of Enlightenment are ... Oct. 20-26 to further their studies. , The Capstone ... remarkable “Masters of Divine Jazz” World Tour which featured ... Korea, Mexico, and South Africa. Cost of the 6-day ... and for seniors age 65 and older. , The ...
(Date:9/16/2014)... September 16, 2014 The global market ... 1,129.8 million by 2020, growing at an estimated CAGR ... new study by Grand View Research, Inc. A growing ... of cost curbing initiatives undertaken by medical device manufacturers ... period. In addition, this technology serves as an effective ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Dr. Eric ... launch of ACLsurgeryLA.com , a specialty website devoted ... As an avid sports lover and athlete, Dr. ... treatment and recovery from injuries to maintain active, healthy ... offer patients a resource dedicated specifically to ACL ...
(Date:9/16/2014)... On September 14, the HearStrong Foundation ... Bills Alumni Foundation VIP Tailgate event outside Ralph Wilson ... NFL Hall-of-Famer Joe DeLamielleure, who also experiences hearing ... her dedication in overcoming hearing difficulties to achieve her ... community to do the same. , Nominated by Hearing ...
(Date:9/16/2014)... September 16, 2014 Recently, UWDress.com, an ... occasion gowns, has announced its special offer for ... company’s fashionable cocktail dresses at a low rate. More ... a discounted shipping cost. , UWDress.com has promised ... clients are able to find the most fashionable items. ...
Breaking Medicine News(10 mins):Health News:Ramtha School Presents Capstone Event in Yelm Oct. 20-26 2Health News:Healthcare 3D Printing Market By Application, By Technology And By Raw Materials Is Expected To Reach USD 1,129.8 Million By 2020: Grand View Research, Inc 2Health News:Healthcare 3D Printing Market By Application, By Technology And By Raw Materials Is Expected To Reach USD 1,129.8 Million By 2020: Grand View Research, Inc 3Health News:Healthcare 3D Printing Market By Application, By Technology And By Raw Materials Is Expected To Reach USD 1,129.8 Million By 2020: Grand View Research, Inc 4Health News:Healthcare 3D Printing Market By Application, By Technology And By Raw Materials Is Expected To Reach USD 1,129.8 Million By 2020: Grand View Research, Inc 5Health News:Healthcare 3D Printing Market By Application, By Technology And By Raw Materials Is Expected To Reach USD 1,129.8 Million By 2020: Grand View Research, Inc 6Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:The HearStrong Foundation and the Buffalo Bills Alumni Foundation Celebrated HearStrong Champion During 2014 Alumni Weekend 2Health News:UWDress.com: Cheap Cocktail Gowns For The Global Market 2
... the July issue of the urology journal BJU International, nearly ... a drug known to treat problems of erection. The users ... ,And 70 per cent of family doctors who ... drug feedback form felt the drug wasn't effective. ...
... early as possible in an effort to reverse its ... leading// cause of disability in people over the age ... have been able to treat the disease and offer ... identified telltale, genetic signs that indicate the early onset ...
... salaries of doctors participating in the anti-quota stir was likely to ... to do so was issued on the direction of Director P ... who was asked to explain the reason behind the order to ... was asked to relinquish charge as Registrar by the Director on ...
... country have complained of failed tubectomy birth-control surgeries and ... Pradesh couple has demanded compensation for two failed tubectomy ... complained that she has become pregnant despite the operation. ... in Himachal Pradesh's Shimla district has urged Chief Minister ...
... disorders, here is a cure for you. Store cord blood ... child to ensure a speedy recovery for your family. // ... first cord blood stem cell in India which will store ... of stem cells that can be used in many ways ...
... Probing the effects of the Chernobyl disaster that took place ... radioactivity are not as harmful// as it is thought to ... exists a certain level of toleration or limit of radioactive ... might stir up a debate over nuclear issues that are ...
Cached Medicine News:Health News:Erection Drug Was Not Useful to Two-Thirds of Its Users 2Health News:Erection Drug Was Not Useful to Two-Thirds of Its Users 3Health News:Researchers Beginning to Identify Genetic Culprits of Arthritis 2Health News:Women Complains of Failed Tubectomy from Two Different States 2
(Date:9/15/2014)... , Sept. 15, 2014  Patients in today,s ... care more frequently in an outpatient setting versus a ... curve and to ensure that patients continue to receive ... the launch of its new internal medicine residency program. ... more often in office, clinic and even virtual settings. ...
(Date:9/15/2014)... , Sept. 15, 2014  Valeant Pharmaceuticals International, Inc. ... its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem ... of its 6.75% Senior Notes due 2017, CUSIP Nos. ... 2014 and has mailed an irrevocable notice of redemption ... a copy of the irrevocable notice of redemption with ...
(Date:9/15/2014)... , Sept. 15, 2014 myMatrixx has extended ... Stanos with an expanded role that includes direct ... Dr. Stanos, a nationally recognized physiatrist and pain management ... to rehabilitation and workers, compensation, is Board Certified in ... American Board of Pain Medicine and subspecialty boarded by ...
Breaking Medicine Technology:Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 2Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 3Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2
... 2009 Convention -- When Shawnae Jebbia won the Miss USA ... career. She appeared at events throughout the world, worked as ... world unexpectedly changed when she was diagnosed with hearing loss. ... had a difficult time understanding and accepting the sudden hearing ...
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERES ), a leading provider ... medical device and related industries, announced today results for the ... Unless otherwise noted, all comparative numbers refer to changes from ... , Financial highlights for the third quarter of 2009: ...
Cached Medicine Technology:Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3ERT Reports Third Quarter 2009 Results 2ERT Reports Third Quarter 2009 Results 3ERT Reports Third Quarter 2009 Results 4ERT Reports Third Quarter 2009 Results 5ERT Reports Third Quarter 2009 Results 6ERT Reports Third Quarter 2009 Results 7ERT Reports Third Quarter 2009 Results 8ERT Reports Third Quarter 2009 Results 9ERT Reports Third Quarter 2009 Results 10ERT Reports Third Quarter 2009 Results 11ERT Reports Third Quarter 2009 Results 12ERT Reports Third Quarter 2009 Results 13
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Bipolar foot activated forceps....
Cushing bayonet....
Bipolar hand activated forceps....
Medicine Products: